TScan Therapeutics, founded in Waltham, United States, is a clinical-stage biopharmaceutical company committed to developing transformative T cell therapies. Their core mission is to harness the untapped potential of the human immune system to create life-changing treatments for patients. TScan focuses on advanced immunotherapy solutions, particularly targeting heme malignancies through their novel T cell receptor (TCR) systems.
Notable achievements include receiving the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation for their two lead TCR-T therapy candidates. TScan's innovative approach has garnered attention within the biotech community, and they have presented at prestigious events like the Jefferies Global Healthcare Conference. Their work is poised to make significant impacts in the field of immunotherapy, offering new hope for patients with challenging conditions.
